Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

Raghav, Kanwal; Siena, Salvatore; Takashima, Atsuo; Kato, Takeshi; Van den Eynde, Marc; Pietrantonio, Filippo; Komatsu, Yoshito; Kawakami, Hisato; Peeters, Marc; Andre, Thierry; Lonardi, Sara; Yamaguchi, Kensei; Tie, Jeanne; Castro, Cristina Gravalos; Hsu, Hung-Chih; Strickler, John H; Kim, Tae-You; Cha, Yongjun; Barrios, Daniel; Yan, Qi

doi:10.1016/S1470-2045(24)00380-2

MAINTENANCE EN COURS / SITE UNDER MAINTENANCE

Une opération de maintenance est en cours: les résultats de recherches et les exportations peuvent être incohérent.
Site under maintenance: search & exportation results could be inconsistent.

Request a copy of the file

Enter the following information to request a copy for the following item: Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

Requesting the following file: 2024_Raghav_Lancet_Oncol.pdf

Back